Board of Directors
An experienced team with a wealth of experience that provides direction for our organization.
The members of the Fidelis Animal Health board bring expertise in diverse areas of the pharmaceutical industry to help us best serve the animal health community with high-quality innovative solutions.
Meet Our Board of Directors:
BARRY LEVINSON, PhD
Barry’s biochemistry background has fueled his lifelong passion for bringing leading-edge healthcare products from conception through to commercialization. As a managing director at Princeton Biopharma Capital Partners, a Fidelis Animal Health board member, and our Chief Development Officer, Barry has been instrumental in bringing our lead product Ethiqa XR® to research institutions around the country and in securing capital to accelerate additional product development.
Barry’s track record of accomplishments in pharmaceuticals and biotech spans more than 40 years. Prior to co-founding Fidelis, he served as Vice President of Business Development at Valeant Pharma (now Bausch Health) and was a founding Vice President (business development) and Chief Scientific Officer at Aton Pharma. His talent and expertise in recognizing new medical uses and spearheading R&D to expand indications was evident at Aton.
Intrigued with entrepreneurship early in his career, Barry began his corporate years at the biotech startup Ecogen. From there, he spent a decade in increasingly senior positions in cardiovascular research and business development for Schering A.G.’s Berlex Labs (now Bayer Healthcare Pharmaceuticals).
After earning his BA in biochemistry with highest honors from Princeton, Barry went on to earn his MS and PhD degrees in molecular biophysics and biochemistry from Yale University.
Mr. Midler holds an MBA from Harvard University and MA and BA degrees in political science from Stanford University.
As an accomplished life sciences entrepreneur, Mr. Steadman has founded multiple companies including two in animal health, Exubrion Therapeutics (board chair) and Velcera Pharmaceuticals (CEO). Exubrion has developed and markets a unique canine osteoarthritis treatment, and Mr. Steadman led Velcera from conception and capital funding through to acquisition by a NYSE-traded strategic player.
Mr. Steadman also brings insights from his experience in leading pharmaceutical companies to his board position at Fidelis. He is former vice president (North American) for Merial Animal Health and successfully built the Australasia region and led the US business at Merck Animal Health.
With a BS in business management and an MS in agricultural economics from The Pennsylvania State University, Mr. Steadman also holds a certificate in executive finance from Harvard Business School.
We’re committed to leading the industry with quality-driven therapeutics.